ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 39.2 Cr.
- Current Price ₹ 30.1
- High / Low ₹ 62.8 / 21.0
- Stock P/E
- Book Value ₹ 51.2
- Dividend Yield 0.00 %
- ROCE -4.12 %
- ROE -14.4 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.59 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.54% over past five years.
- Company has a low return on equity of -7.50% over last 3 years.
- Contingent liabilities of Rs.15.7 Cr.
- Promoters have pledged or encumbered 44.9% of their holding.
- Company has high debtors of 264 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 37 | 55 | 67 | 75 | 121 | 126 | 154 | 349 | 207 | 131 | 90 | |
| 30 | 34 | 50 | 60 | 68 | 110 | 114 | 139 | 283 | 195 | 122 | 92 | |
| Operating Profit | 5 | 3 | 5 | 6 | 7 | 12 | 12 | 15 | 66 | 12 | 10 | -2 |
| OPM % | 14% | 8% | 9% | 10% | 10% | 10% | 10% | 10% | 19% | 6% | 7% | -2% |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 10 | -1 | 2 | |
| Interest | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 8 | 11 | 10 | 7 |
| Depreciation | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 9 | 8 | 6 |
| Profit before tax | 0 | 1 | 2 | 4 | 5 | 8 | 8 | 10 | 53 | 2 | -9 | -13 |
| Tax % | 56% | 32% | 25% | 26% | 25% | 30% | 28% | 26% | 25% | 132% | -2% | -20% |
| 0 | 0 | 2 | 3 | 4 | 6 | 6 | 7 | 40 | -1 | -9 | -10 | |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | -43% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| Last Year: | -14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 10 | 13 | 13 | 13 |
| Reserves | -1 | -1 | 1 | 4 | 18 | 24 | 29 | 36 | 73 | 72 | 64 | 54 |
| 11 | 10 | 12 | 14 | 17 | 22 | 21 | 42 | 61 | 56 | 59 | 71 | |
| 11 | 13 | 19 | 25 | 28 | 30 | 39 | 58 | 124 | 111 | 81 | 71 | |
| Total Liabilities | 25 | 26 | 35 | 47 | 68 | 81 | 94 | 142 | 269 | 252 | 217 | 209 |
| 9 | 9 | 9 | 9 | 9 | 21 | 21 | 22 | 82 | 79 | 53 | 53 | |
| CWIP | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| 16 | 17 | 26 | 38 | 47 | 60 | 73 | 120 | 183 | 170 | 161 | 153 | |
| Total Assets | 25 | 26 | 35 | 47 | 68 | 81 | 94 | 142 | 269 | 252 | 217 | 209 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 3 | 2 | 3 | 1 | 7 | 5 | -11 | 27 | 26 | -13 | -2 | |
| -2 | -2 | -3 | -3 | -13 | -1 | -2 | -8 | -42 | -9 | 20 | -2 | |
| -1 | -1 | 2 | -0 | 13 | -4 | -4 | 19 | 15 | -17 | -7 | 4 | |
| Net Cash Flow | 0 | -0 | 1 | -0 | 1 | 3 | -1 | -0 | 0 | -0 | -0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 62 | 109 | 139 | 156 | 126 | 133 | 139 | 104 | 138 | 193 | 264 |
| Inventory Days | 84 | 84 | 47 | 45 | 53 | 27 | 41 | 68 | 46 | 93 | 143 | 228 |
| Days Payable | 129 | 130 | 133 | 163 | 154 | 91 | 106 | 159 | 105 | 154 | 244 | 334 |
| Cash Conversion Cycle | 34 | 16 | 22 | 21 | 56 | 62 | 69 | 48 | 45 | 77 | 92 | 158 |
| Working Capital Days | 28 | 19 | 10 | 14 | 48 | 40 | 53 | 47 | 22 | 28 | 75 | 72 |
| ROCE % | 14% | 17% | 26% | 29% | 22% | 24% | 22% | 20% | 54% | 9% | 2% | -4% |
Documents
Announcements
-
Board Meeting Intimation for Conducting Board Meeting To Consider And Approve Unaudited Standalone & Consolidated Financial Results For The First Quarter Ended 30Th June, 2025.
2d - Board meeting on 14 Aug 2025 to approve Q1 FY26 financial results; trading window closed from 1 July.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Jul - Compliance certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2025.
-
Closure of Trading Window
21 Jun - Trading window closed from July 1, 2025 till 48 hours after Q1 June 30, 2025 results declaration.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Jun - Newspaper disclosure for the FY ended 31.03.2025.
- Financial Year Results For The Year Ended 31.03.2025 30 May
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)